Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
THLD's Cash to Debt is ranked higher than
94% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. THLD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
THLD' s Cash to Debt Range Over the Past 10 Years
Min: 17.14  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset -0.48
THLD's Equity to Asset is ranked lower than
96% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. THLD: -0.48 )
Ranked among companies with meaningful Equity to Asset only.
THLD' s Equity to Asset Range Over the Past 10 Years
Min: -0.86  Med: 0.02 Max: 0.88
Current: -0.48
-0.86
0.88
Interest Coverage No Debt
THLD's Interest Coverage is ranked higher than
91% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. THLD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
THLD' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: -9.29
M-Score: -2.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -223.34
THLD's Operating margin (%) is ranked lower than
62% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. THLD: -223.34 )
Ranked among companies with meaningful Operating margin (%) only.
THLD' s Operating margin (%) Range Over the Past 10 Years
Min: -48445.16  Med: -1776.88 Max: -208.28
Current: -223.34
-48445.16
-208.28
Net-margin (%) -216.38
THLD's Net-margin (%) is ranked lower than
62% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. THLD: -216.38 )
Ranked among companies with meaningful Net-margin (%) only.
THLD' s Net-margin (%) Range Over the Past 10 Years
Min: -41375.81  Med: -1702.83 Max: -146.61
Current: -216.38
-41375.81
-146.61
ROA (%) -42.94
THLD's ROA (%) is ranked lower than
64% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. THLD: -42.94 )
Ranked among companies with meaningful ROA (%) only.
THLD' s ROA (%) Range Over the Past 10 Years
Min: -132.78  Med: -68.06 Max: -25.02
Current: -42.94
-132.78
-25.02
ROC (Joel Greenblatt) (%) -6510.89
THLD's ROC (Joel Greenblatt) (%) is ranked lower than
83% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. THLD: -6510.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
THLD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7379.85  Med: -2871.74 Max: -1147.57
Current: -6510.89
-7379.85
-1147.57
EBITDA Growth (3Y)(%) -9.80
THLD's EBITDA Growth (3Y)(%) is ranked lower than
59% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. THLD: -9.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
THLD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -73.4  Med: -42.60 Max: -9.8
Current: -9.8
-73.4
-9.8
EPS Growth (3Y)(%) -13.80
THLD's EPS Growth (3Y)(%) is ranked lower than
61% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. THLD: -13.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
THLD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -85.5  Med: -45.30 Max: 2.8
Current: -13.8
-85.5
2.8
» THLD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

THLD Guru Trades in Q4 2014

Jim Simons 177,615 sh (+336.40%)
First Eagle Investment 1,377,448 sh (+26.17%)
» More
Q1 2015

THLD Guru Trades in Q1 2015

Jim Simons 346,308 sh (+94.98%)
First Eagle Investment 1,405,768 sh (+2.06%)
» More
Q2 2015

THLD Guru Trades in Q2 2015

Jim Simons 422,103 sh (+21.89%)
First Eagle Investment 1,270,768 sh (-9.60%)
» More
Q3 2015

THLD Guru Trades in Q3 2015

Jim Simons 454,200 sh (+7.60%)
First Eagle Investment 500,000 sh (-60.65%)
» More
» Details

Insider Trades

Latest Guru Trades with THLD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 1.28
THLD's P/S is ranked higher than
94% of the 1126 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. THLD: 1.28 )
Ranked among companies with meaningful P/S only.
THLD' s P/S Range Over the Past 10 Years
Min: 1.28  Med: 37.36 Max: 1242
Current: 1.28
1.28
1242
EV-to-EBIT 1.10
THLD's EV-to-EBIT is ranked higher than
88% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 20.78 vs. THLD: 1.10 )
Ranked among companies with meaningful EV-to-EBIT only.
THLD' s EV-to-EBIT Range Over the Past 10 Years
Min: -22.4  Med: -1.00 Max: 39.3
Current: 1.1
-22.4
39.3
EV-to-EBITDA 1.13
THLD's EV-to-EBITDA is ranked higher than
88% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 17.31 vs. THLD: 1.13 )
Ranked among companies with meaningful EV-to-EBITDA only.
THLD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -23.3  Med: -1.00 Max: 37.5
Current: 1.13
-23.3
37.5
Current Ratio 2.57
THLD's Current Ratio is ranked lower than
67% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. THLD: 2.57 )
Ranked among companies with meaningful Current Ratio only.
THLD' s Current Ratio Range Over the Past 10 Years
Min: 1.48  Med: 5.04 Max: 13.48
Current: 2.57
1.48
13.48
Quick Ratio 2.57
THLD's Quick Ratio is ranked lower than
64% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. THLD: 2.57 )
Ranked among companies with meaningful Quick Ratio only.
THLD' s Quick Ratio Range Over the Past 10 Years
Min: 1.48  Med: 5.04 Max: 13.48
Current: 2.57
1.48
13.48
Days Sales Outstanding 99.96
THLD's Days Sales Outstanding is ranked lower than
70% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. THLD: 99.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
THLD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 179.7  Med: 528.56 Max: 972.69
Current: 99.96
179.7
972.69

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.03
THLD's Price/Median PS Value is ranked higher than
99% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. THLD: 0.03 )
Ranked among companies with meaningful Price/Median PS Value only.
THLD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.08  Med: 0.65 Max: 31.26
Current: 0.03
0.08
31.26
Price/Graham Number 0.13
THLD's Price/Graham Number is ranked higher than
98% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 2.40 vs. THLD: 0.13 )
Ranked among companies with meaningful Price/Graham Number only.
THLD' s Price/Graham Number Range Over the Past 10 Years
Min: 0.95  Med: 1.94 Max: 2.55
Current: 0.13
0.95
2.55
Earnings Yield (Greenblatt) (%) 90.06
THLD's Earnings Yield (Greenblatt) (%) is ranked higher than
96% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. THLD: 90.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
THLD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.5  Med: 264.15 Max: 14657.5
Current: 90.06
2.5
14657.5

More Statistics

Revenue(Mil) $15
EPS $ -0.48
Beta1.55
Short Percentage of Float3.38%
52-Week Range $0.27 - 5.28
Shares Outstanding(Mil)71.46

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 41 102
EPS($) -0.55 -0.81 -0.08 0.52
EPS without NRI($) -0.55 -0.81 -0.08 0.52

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NZW1.Germany,
Threshold Pharmaceuticals Inc is a Delaware corporation incorporated on October 17, 2001. It's a biotechnology company focused on the discovery and development of drugs targeting the microenvironment of solid tumors as novel treatments for patients living with cancer. The microenvironment of these tissues is characterized by hypoxia or lack of oxygen. Its hypoxia activated prodrug ("HAP") product candidates, including TH-302, are designed to specifically target the hypoxic microenvironment of tumors by selective activation of the prodrug to release a potent cytotoxin. Its focus is on product candidates for the treatment of patients with cancer. Its clinical development efforts are currently engaged in TH-302, for which it entered a license and co-development agreement with Merck KGaA for development and commercialization. TH-302 is a novel drug candidate that is activated under severe hypoxic conditions and was designed to specifically target the severe hypoxic regions that are believed to be present in all solid tumors and hematologic malignancies. The production of TH-302 employs small molecule organic chemistry procedures that are standard for the pharmaceutical industry. It currently relies on contract manufacturers for the manufacture of active pharmaceutical ingredient ("API"), and final drug product of TH-302. Under its license and co-development agreement with Merck KGaA, the Company is dependent on Merck for clinical and commercial supply of TH-302, except for clinical trials for United States approval of TH-302 for soft tissue sarcoma and for any other clinical trials for which it is responsible. For these latter cases, it can obtain clinical supply directly from existing or new suppliers. It currently uses contract manufacturers to manufacture TH-302 API and TH-302 drug product. The commercial sale for pancreatic cancer, TH-302 would compete with Gemzar, marketed by Eli Lilly and Company; Tarceva, marketed by Genentech and Astellas Oncology; Abraxane marketed by Celgene; and FOLFIRINOX. The manufacturing and marketing of its potential products and its ongoing research and development activities are subject to extensive regulation by the FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries.
» More Articles for THLD

Headlines

Articles On GuruFocus.com
Tuesday Pre-Market Insights: THLD, PLL, AOL, CALL May 12 2015 
Threshold Pharmaceuticals Inc. (THLD) CEO Harold E Selick buys 47,619 Shares Mar 15 2011 
Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 
Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2010 
Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
Threshold Pharmaceuticals Inc. (THLD) CEO Harold E Selick buys 52,356 Shares Oct 06 2009 
Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2009 
Threshold Pharmaceuticals Inc. (THLD) CEO Harold E Selick buys 20,000 Shares Jun 05 2009 
Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Jan 22 2016
Threshold Pharmaceuticals and Merck KGaA, Darmstadt, Germany Agree to Key Terms for the Licensing... Jan 11 2016
Threshold Pharmaceuticals and Merck KGaA, Darmstadt, Germany Agree to Key Terms for the Licensing... Jan 11 2016
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jan 11 2016
Threshold Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 22 2015
After cancer drug trials crash, Peninsula biotech sheds one-third of jobs Dec 18 2015
Threshold Pharmaceuticals Announces Workforce Reduction Dec 18 2015
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Dec 18 2015
Threshold Pharmaceuticals Announces Workforce Reduction Dec 18 2015
The Only Bit of "Good News" From 2015 Dec 14 2015
5 Key BioPharma Movers That Cannot Be Ignored Dec 12 2015
5 Companies That Absolutely Destroyed Shareholders This Past Week Dec 12 2015
THRESHOLD PHARMACEUTICALS INC Financials Dec 08 2015
INVESTOR UPDATE: NASDAQ/NYSE Volatility Alert for December 8, 2015 Dec 08 2015
Peninsula biotech sinks on two cancer failures Dec 07 2015
Why Are Investors Selling These Stocks Today? Dec 07 2015
Why Threshold Pharma Is Imploding Dec 07 2015
Threshold Pharmaceuticals’ stock plunges after drug trial disappoints Dec 07 2015
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 07 2015
Threshold Pharmaceuticals Announces Its Two Phase 3 Studies Evaluating Evofosfamide Did Not Meet... Dec 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK